Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma

British Journal of Cancer

Volumn 112, Issue 7, 2015, Pages 1241-1246

  Lai, N S ^a   Wu, D G ^a   Fang, X G ^a   Lin, Y C ^b   Chen, S S ^a   Li, Z B ^a   Xu, S S ^a  

^a WANNAN MEDICAL COLLEGE   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Diagnosis; Glioma; MicroRNA 210; Prognosis

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA; MICRORNA; MICRORNA 161; MICRORNA 210; RNA; UNCLASSIFIED DRUG; MIRN210 MICRORNA, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; BLOOD SAMPLING; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CHINA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DNA SYNTHESIS; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL SCHOOL; NEUROSURGERY; NON INVASIVE PROCEDURE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PILOCYTIC ASTROCYTOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SERUM; TUMOR VOLUME; ANALYSIS OF VARIANCE; BLOOD; CENTRAL NERVOUS SYSTEM TUMOR; COHORT ANALYSIS; GENETICS; PATHOLOGY; PROGNOSIS;

ADULT; ANALYSIS OF VARIANCE; BIOMARKERS, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; COHORT STUDIES; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; NEOPLASM GRADING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84938550037     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.91     Document Type: Article

References (45)

1. Ahluwalia MS, Chang SM (2014) Medical therapy of gliomas. J Neurooncol 119: 503-512.
2. Auffinger B, Thaci B, Ahmed A, Ulasov I, Lesniak MS (2013) MicroRNA targeting as a therapeutic strategy against glioma. Curr Mol Med 13: 535-542.
3. Chen Z, Li Y, Zhang H, Huang P, Luthra R (2010) Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene 29: 4362-4368.
4. Chio CC, Lin JW, Cheng HA, Chiu WT, Wang YH, Wang JJ, Hsing CH, Chen RM (2013) MicroRNA-210 targets antiapoptotic bcl-2 expression and mediates hypoxia-induced apoptosis of neuroblastoma cells. Arch Toxicol 87: 459-468.
5. Cui H, Seubert B, Stahl E, Dietz H, Reuning U, Moreno-Leon L, Ilie M, Hofman P, Nagase H, Mari B, Kruger A (2014) Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene 29: 300.
6. Eilertsen M, Andersen S, Al-Saad S, Richardsen E, Stenvold H, Hald SM, Al-Shibli K, Donnem T, Busund LT, Bremnes RM (2014) Positive prognostic impact of miR-210 in non-small cell lung cancer. Lung Cancer 83: 272-278.
7. Gee HE, Ivan C, Calin GA, Ivan M (2014) Hypoxamirs and cancer: from biology to targeted therapy. Antioxid Redox Signal 21: 1220-1238.
8. Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le Q-T, Koong AC (2010) Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol 3: 109-113.
9. Ivan M, Huang X (2014) MiR-210: fine-tuning the hypoxic response. Adv Exp Med Biol 772: 205-227.
10. Iwamoto H, Kanda Y, Sejima T, Osaki M, Okada F, Takenaka A (2014) Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol 44: 53-58.
11. Joosse SA, Muller V, Steinbach B, Pantel K, Schwarzenbach H (2014) Circulating cell-free cancer-testis mage-A RNA, boris RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases. Br J Cancer 111: 909-917.
12. Kawaguchi T, Komatsu S, Ichikawa D, Morimura R, Tsujiura M, Konishi H, Takeshita H, Nagata H, Arita T, Hirajima S, Shiozaki A, Ikoma H, Okamoto K, Ochiai T, Taniguchi H, Otsuji E (2013) Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer 108: 361-369.
13. Kim HW, Mallick F, Durrani S, Ashraf M, Jiang S, Haider KH (2012) Concomitant activation of miR-107/pdcd10 and hypoxamir-210/casp8ap2 and their role in cytoprotection during ischemic preconditioning of stem cells. Antioxid Redox Signal 17: 1053-1065.
14. Lai NS, Dong QS, Ding H, Miao ZL, Lin YC (2014) MicroRNA-210 overexpression predicts poorer prognosis in glioma patients. J Clin Neurosci 21: 755-760.
15. Li L, Huang K, You Y, Fu X, Hu L, Song L, Meng Y (2014) Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis. Int J Oncol 44: 2111-2120.
16. Li M, Li J, Liu L, Li W, Yang Y, Yuan J (2013a) MicroRNA in human glioma. Cancers 5: 1306-1331.
17. Li ZH, Zhang H, Yang ZG, Wen GQ, Cui YB, Shao GG (2013b) Prognostic significance of serum microRNA-210 levels in nonsmall-cell lung cancer. J Int Med Res 41: 1437-1444.
18. Liu T, Zhao L, Chen W, Li Z, Hou H, Ding L, Li X (2014) Inactivation of von hippel-lindau increases ovarian cancer cell aggressiveness through the HIF1alpha/miR-210/vmp1 signaling pathway. Int J Mol Med 33: 1236-1242.
19. Menendez P, Padilla D, Villarejo P, Palomino T, Nieto P, Menendez JM, Rodriguez-Montes JA (2013) Prognostic implications of serum microRNA-21 in colorectal cancer. J Surg Oncol 108: 369-373.
20. Merlo A, de Quiros SB, de Santa-Maria IS, Pitiot AS, Balbin M, Astudillo A, Scola B, Aristegui M, Quer M, Suarez C, Chiara MD (2013) Identification of somatic vhl gene mutations in sporadic head and neck paragangliomas in association with activation of the HIF-1alpha/miR-210 signaling pathway. J Clin Endocrinol Metab 98: 2013-1636.
21. Nikaki A, Piperi C, Papavassiliou AG (2012) Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy. Expert Opin Investig Drugs 21: 1475-1488.
22. Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310: 1842-1850.
23. Pizzini S, Bisognin A, Mandruzzato S, Biasiolo M, Facciolli A, Perilli L, Rossi E, Esposito G, Rugge M, Pilati P, Mocellin S, Nitti D, Bortoluzzi S, Zanovello P (2013) Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics 14: 1471-2164.
24. Puissegur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K, Maurin T, Lebrigand K, Cardinaud B, Hofman V, Fourre S, Magnone V, Ricci JE, Pouyssegur J, Gounon P, Hofman P, Barbry P, Mari B (2011) MiR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ 18: 465-478.
25. Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y (2013) Interactions of miR-323/ miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med 11: 1479-5876.
26. Redova M, Sana J, Slaby O (2013) Circulating miRNAs as new blood-based biomarkers for solid cancers. Future Oncol 9: 387-402.
27. Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, Eisele G, Weller M, Keller A (2011) A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem 118: 449-457.
28. Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M, Carinci F (2010) MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol 23: 1229-1234.
29. Shankar JJ, Woulfe J, Silva VD, Nguyen TB (2013) Evaluation of perfusion CT in grading and prognostication of high-grade gliomas at diagnosis: a pilot study. AJR Am J Roentgenol 200: W504-W509.
30. Srivastava A, Goldberger H, Dimtchev A, Marian C, Soldin O, Li X, Collins SP, Suy S, Kumar D (2014) Circulatory miR-628-5p is downregulated in prostate cancer patients. Tumour Biol 35: 4867-4873.
31. Szabo DR, Luconi M, Szabo PM, Toth M, Szucs N, Horanyi J, Nagy Z, Mannelli M, Patocs A, Racz K, Igaz P (2014) Analysis of circulating microRNAs in adrenocortical tumors. Lab Invest 94: 331-339.
32. Takikawa T, Masamune A, Hamada S, Nakano E, Yoshida N, Shimosegawa T (2013) MiR-210 regulates the interaction between pancreatic cancer cells and stellate cells. Biochem Biophys Res Commun 437: 433-439.
33. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A (2013) Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst 105: 849-859.
34. Ulivi P, Zoli W (2014) MiRNAs as non-invasive biomarkers for lung cancer diagnosis. Molecules 19: 8220-8237.
35. Wang J, Zhao J, Shi M, Ding Y, Sun H, Yuan F, Zou Z (2014a) Elevated expression of miR-210 predicts poor survival of cancer patients: a systematic review and meta-analysis. PLoS One 9: e89223.
36. Wang Y, Kim S, Kim IM (2014b) Regulation of metastasis by microRNAs in ovarian cancer. Front Oncol 4: 143.
37. Wang Z, Yin B, Wang B, Ma Z, Liu W, Lv G (2014c) MicroRNA-210 promotes proliferation and invasion of peripheral nerve sheath tumor cells targeting EFNA3. Oncol Res 21: 145-154.
38. Xiao N, Gu W, Wang H, Deng Y, Shi X, Ye L (2014) T1-T2 dual-modal MRI of brain gliomas using pegylated gd-doped iron oxide nanoparticles. J Colloid Interface Sci 417: 159-165.
39. Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F, Wang J, Li L, Zhou X, Li N, Pan H, Zhang J, Zen K, Zhang CY, Zhang C (2013) Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer 132: 116-127.
40. Ying Q, Liang L, Guo W, Zha R, Tian Q, Huang S, Yao J, Ding J, Bao M, Ge C, Yao M, Li J, He X (2011) Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology 54: 2064-2075.
41. Zanutto S, Pizzamiglio S, Ghilotti M, Bertan C, Ravagnani F, Perrone F, Leo E, Pilotti S, Verderio P, Gariboldi M, Pierotti MA (2014) Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer. Br J Cancer 110: 1001-1007.
42. Zeng L, He X, Wang Y, Tang Y, Zheng C, Cai H, Liu J, Fu Y, Yang GY (2014) MicroRNA-210 overexpression induces angiogenesis and neurogenesis in the normal adult mouse brain. Gene Therapy 21: 37-43.
43. Zhan M, Li Y, Hu B, He X, Huang J, Zhao Y, Fu S, Lu L (2014) Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol 13: 00448-00445.
44. Zhang K, Zhang Y, Liu C, Xiong Y, Zhang J (2014) MicroRNAs in the diagnosis and prognosis of breast cancer and their therapeutic potential (review). Int J Oncol 45: 950-958.
45. Zhao A, Li G, Peoc'h M, Genin C, Gigante M (2013) Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol 94: 115-120.